What effects do hemodilution and blood transfusion during cardiopulmonary bypass have on renal outcomes?
Mark Stafford-Smith* and Mark F Newman
Correspondence *Duke University Medical Center, Department of Anesthesiology, Box 3094 DUMC, Durham, NC 27710, USA
Email staff002@mc.duke.edu
This article has no abstract so we have provided the first paragraph of the full text.
The decision made daily by clinicians to tolerate significant anemia during CPB has recently been questioned, because very low CPB hematocrit values (i.e. <20%) are emerging as an important predictor of adverse outcomes, including renal dysfunction after cardiac surgery.1, 2 Ironically, one alternative to tolerating extreme CPB hemodilution—transfusion—has also been implicated as a risk factor for poor outcome.1 Acute renal injury after cardiac surgery is common and is highly associated with mortality and other major postoperative complications. Therefore, there is a pressing need to clarify the optimal management of hematocrit and transfusion during CPB.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Youth has its privileges: maturation inhibits DC cross-primingNature Immunology News and Views (01 Feb 2006)
